Pub Date : 2019-07-15DOI: 10.19080/ctoij.2019.14.555888
Pawan Kumar
Introduction: Metastatic spinal cord compression (MSCC) is a most commonly encountered emergency in oncology, that can lead to permanent paraplegia if left untreated or treatment delayed, so it is essential to diagnose early and treat aggressively to preserve or improve the patient’s quality of life. We analyzed the incident and the effect of common interventions on the outcome in these patients. Material and Methods: We prospectively evaluated 80 patients of MSCC without any intervention in the year 2017 and collected all relevant patient and disease characteristics. All patients received corticosteroids. Seven patients were operated, 59 patients treated by radiotherapy and 3 patients were treated by surgery followed by radiotherapy. Results: Most of the patients were in the age group of 40-70 years with male gender preponderance. Lung cancer was the most common incident (46.25%) malignancy followed by breast, myeloma and prostate cancer. Dorsal spine was the most common site of compression (50.5%) followed by lumbar spine (40.8%) and cervical spine (8.7%). 62 (77.5%) patients were presented with pain at affected site and 60 (75%) were presented with neurological motor deficit. 54 (87%) patients got relieved from pain and only 23(38%) patients had motor improvement after treatment. Conclusion: Patients presented 7-10 days after onset of neurological deficit were associated with poor outcome in neurological function, but radiotherapy proved an important modality for pain relief in MSCC and also beneficial in motor function preservation if instituted early. before predictive of response to treatment and overall outcome of motor functions.
{"title":"Metastatic Spinal Cord Compression: A Prospective Observational Study at a Tertiary Care Center of North India","authors":"Pawan Kumar","doi":"10.19080/ctoij.2019.14.555888","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555888","url":null,"abstract":"Introduction: Metastatic spinal cord compression (MSCC) is a most commonly encountered emergency in oncology, that can lead to permanent paraplegia if left untreated or treatment delayed, so it is essential to diagnose early and treat aggressively to preserve or improve the patient’s quality of life. We analyzed the incident and the effect of common interventions on the outcome in these patients. Material and Methods: We prospectively evaluated 80 patients of MSCC without any intervention in the year 2017 and collected all relevant patient and disease characteristics. All patients received corticosteroids. Seven patients were operated, 59 patients treated by radiotherapy and 3 patients were treated by surgery followed by radiotherapy. Results: Most of the patients were in the age group of 40-70 years with male gender preponderance. Lung cancer was the most common incident (46.25%) malignancy followed by breast, myeloma and prostate cancer. Dorsal spine was the most common site of compression (50.5%) followed by lumbar spine (40.8%) and cervical spine (8.7%). 62 (77.5%) patients were presented with pain at affected site and 60 (75%) were presented with neurological motor deficit. 54 (87%) patients got relieved from pain and only 23(38%) patients had motor improvement after treatment. Conclusion: Patients presented 7-10 days after onset of neurological deficit were associated with poor outcome in neurological function, but radiotherapy proved an important modality for pain relief in MSCC and also beneficial in motor function preservation if instituted early. before predictive of response to treatment and overall outcome of motor functions.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80253605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-10DOI: 10.19080/ctoij.2019.14.555886
A. kumar Jha
Cancer is a type of disease that spreads due to uncontrolled of cell growth due to the collection of defects or variation in their DNA and with imminence to attack or distribute to other parts of the body. Cancer is specified as a wide group of several infections normally characterized by persistently uncontrolled and unnatural at usual cell yield, where cell proliferation comes via mitotic deregulations and thus contributes to overgrowth of cancerous cells. In the case of malignancy, these cells may transmigrate from one body parts to other in the form of tumors and metastasis in blood stream sand lymphatic system (Ochwang et al., 2015 and Srivatava et al., 2015). Various studies have demonstrated that the cancer danger at the level of particular organs is due to exposure to particular environmental chemicals, biological factors (as Human Papilloma virus, Helicobacter hepticus, HIV1, HBV) or physical factors (such as X-radiation, gamma radiation) (Zulkipli et al., 2015). Research proposes that most malignancies are caused by a dysfunction of multiple genes coding for macromolecules like as growth factors, growth factor receptors, anti-apoptotic proteins, transcription factors, and tumor suppressors, all of which establish the aim for disease treatment (Cogliano et al., 2011 and Vogelstein et al., 2004).
癌症是一种由于细胞生长不受控制而传播的疾病，这种不受控制是由于细胞DNA中的缺陷或变异的聚集，并且迫在眉睫地攻击或扩散到身体的其他部位。癌症被定义为一组广泛的几种感染，通常以细胞产量持续不受控制和不自然为特征，其中细胞增殖来自有丝分裂失调，从而导致癌细胞过度生长。在恶性肿瘤的情况下，这些细胞可能以肿瘤的形式从身体的一个部位转移到另一个部位，并在血液和淋巴系统中转移(Ochwang et al.， 2015和Srivatava et al.， 2015)。各种研究表明，特定器官水平的癌症危险是由于暴露于特定的环境化学物质，生物因素(如人类乳头瘤病毒，hepobacter Helicobacter, hiv - 1, HBV)或物理因素(如x射线，伽马射线)(Zulkipli等人，2015)。研究表明，大多数恶性肿瘤是由生长因子、生长因子受体、抗凋亡蛋白、转录因子、肿瘤抑制因子等大分子编码基因的多种功能障碍引起的，这些大分子编码基因的功能障碍是疾病治疗的目标(Cogliano et al.， 2011 and Vogelstein et al.， 2004)。
{"title":"Apoptosis Caused by Natural Compounds in Cervical Cancer Cell Line","authors":"A. kumar Jha","doi":"10.19080/ctoij.2019.14.555886","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555886","url":null,"abstract":"Cancer is a type of disease that spreads due to uncontrolled of cell growth due to the collection of defects or variation in their DNA and with imminence to attack or distribute to other parts of the body. Cancer is specified as a wide group of several infections normally characterized by persistently uncontrolled and unnatural at usual cell yield, where cell proliferation comes via mitotic deregulations and thus contributes to overgrowth of cancerous cells. In the case of malignancy, these cells may transmigrate from one body parts to other in the form of tumors and metastasis in blood stream sand lymphatic system (Ochwang et al., 2015 and Srivatava et al., 2015). Various studies have demonstrated that the cancer danger at the level of particular organs is due to exposure to particular environmental chemicals, biological factors (as Human Papilloma virus, Helicobacter hepticus, HIV1, HBV) or physical factors (such as X-radiation, gamma radiation) (Zulkipli et al., 2015). Research proposes that most malignancies are caused by a dysfunction of multiple genes coding for macromolecules like as growth factors, growth factor receptors, anti-apoptotic proteins, transcription factors, and tumor suppressors, all of which establish the aim for disease treatment (Cogliano et al., 2011 and Vogelstein et al., 2004).","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83260384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-08DOI: 10.19080/ctoij.2019.14.555885
Meenu Gupta
Aim: To determine the response and toxicity of extended field radiation therapy and concurrent chemotherapy on uterine cervical cancer patients with para - aortic lymph node metastasis. Methods: Forty patients with cervical cancer with para -aortic lymphadenopathy metastasis were treated by photons on LINAC with extended field radiotherapy (46-50Gy/23-25#) along with weekly concurrent cisplatin (35mg/m2) followed by 3 sessions of weekly intracavitory brachytherapy (7Gy per session by HDR Ir-192) at our institution. The primary endpoint was to assess efficacy in terms of response to the treatment. The secondary endpoint was to assess tolerance of treatment in terms of toxicities (hematological and non-hematological). Results: Complete clinical response in pelvis and para-aortic disease were observed in 28(70%) and 27(67.5%) patients. Partial clinical response in pelvis and para-aortic disease were observed in 11(27.5%) and 12(30%) of patients. One patient did not respond to the treatment and had progression of disease. Anemia grade 1-2 was seen in 22(55%) patients. Neutropenia grade 1-2 was seen in 10(25%) of patients. Thrombocytopenia grade 1 was seen in only 2(5%) of patients. None of the patient had grade 4 hematological
{"title":"Efficacy and Tolerance of Extended Field Radiation Therapy in Uterine Cervical Cancer Patients with Para-Aortic Lymph Node Metastasis","authors":"Meenu Gupta","doi":"10.19080/ctoij.2019.14.555885","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555885","url":null,"abstract":"Aim: To determine the response and toxicity of extended field radiation therapy and concurrent chemotherapy on uterine cervical cancer patients with para - aortic lymph node metastasis. Methods: Forty patients with cervical cancer with para -aortic lymphadenopathy metastasis were treated by photons on LINAC with extended field radiotherapy (46-50Gy/23-25#) along with weekly concurrent cisplatin (35mg/m2) followed by 3 sessions of weekly intracavitory brachytherapy (7Gy per session by HDR Ir-192) at our institution. The primary endpoint was to assess efficacy in terms of response to the treatment. The secondary endpoint was to assess tolerance of treatment in terms of toxicities (hematological and non-hematological). Results: Complete clinical response in pelvis and para-aortic disease were observed in 28(70%) and 27(67.5%) patients. Partial clinical response in pelvis and para-aortic disease were observed in 11(27.5%) and 12(30%) of patients. One patient did not respond to the treatment and had progression of disease. Anemia grade 1-2 was seen in 22(55%) patients. Neutropenia grade 1-2 was seen in 10(25%) of patients. Thrombocytopenia grade 1 was seen in only 2(5%) of patients. None of the patient had grade 4 hematological","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89498502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-27DOI: 10.19080/ctoij.2019.14.555884
Biplab Misra
Anemia is a common challenge among oncologists. Anemia has been directly implicated in the prognosis of cancer patients. Furthermore, correction of anemia-related symptoms can significantly improve the quality of life in these patients. We performed a systematic review of literature to improve our present knowledge on anemia in cancer patients. The data for review were identified by searching PubMed and Google Scholar and based on the recommendations from professional compendiums such as those by the National Comprehensive Cancer Network and European Society of Medical Oncology. The level of Hemoglobin is an established prognostic factor in many cancer patients. One of the reasons for this is that anemia will result in hypoxia and, subsequently, in tumor resistance to chemotherapy and radiotherapy. This review suggests that the ESAs (Erythropoietin Stimulating Agents) and intravenous iron should be used to maintain target hemoglobin level of 10 g/dl while the patient is receiving chemotherapy. However, long-term effect of intravenous iron treatment, ESAs use, and red blood cell transfusions should be further investigated.
{"title":"Pathophysiology & Management of Anemia in Cancer Patients: A Systematic Review Nanda","authors":"Biplab Misra","doi":"10.19080/ctoij.2019.14.555884","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555884","url":null,"abstract":"Anemia is a common challenge among oncologists. Anemia has been directly implicated in the prognosis of cancer patients. Furthermore, correction of anemia-related symptoms can significantly improve the quality of life in these patients. We performed a systematic review of literature to improve our present knowledge on anemia in cancer patients. The data for review were identified by searching PubMed and Google Scholar and based on the recommendations from professional compendiums such as those by the National Comprehensive Cancer Network and European Society of Medical Oncology. The level of Hemoglobin is an established prognostic factor in many cancer patients. One of the reasons for this is that anemia will result in hypoxia and, subsequently, in tumor resistance to chemotherapy and radiotherapy. This review suggests that the ESAs (Erythropoietin Stimulating Agents) and intravenous iron should be used to maintain target hemoglobin level of 10 g/dl while the patient is receiving chemotherapy. However, long-term effect of intravenous iron treatment, ESAs use, and red blood cell transfusions should be further investigated.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80972326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-17DOI: 10.19080/ctoij.2019.14.555883
Ravinderpal Kour Sodhi
Metals are essential cellular components selected by nature to function in several indispensable biochemical processes for living organisms. Transition metal complexes are important in catalysis, materials synthesis, photochemistry, and biological systems. Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. The use of metals and their salts for medicinal purposes has been present throughout history. With the advancement in the field of inorganic chemistry the role of transition metal complexes as therapeutic compounds is becoming increasingly important. Recent advances in inorganic chemistry have made possible formation of number of transition metal complexes with organic ligand of interest, which can be used as therapeutic agent. This review illustrates the role of metals and the recent progress in the field of medicinal bioinorganic chemistry with new approaches to the design of innovative metal-based drugs and their application.
{"title":"Metal Complexes in Medicine: An Overview and Update from Drug Design Perspective","authors":"Ravinderpal Kour Sodhi","doi":"10.19080/ctoij.2019.14.555883","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555883","url":null,"abstract":"Metals are essential cellular components selected by nature to function in several indispensable biochemical processes for living organisms. Transition metal complexes are important in catalysis, materials synthesis, photochemistry, and biological systems. Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. The use of metals and their salts for medicinal purposes has been present throughout history. With the advancement in the field of inorganic chemistry the role of transition metal complexes as therapeutic compounds is becoming increasingly important. Recent advances in inorganic chemistry have made possible formation of number of transition metal complexes with organic ligand of interest, which can be used as therapeutic agent. This review illustrates the role of metals and the recent progress in the field of medicinal bioinorganic chemistry with new approaches to the design of innovative metal-based drugs and their application.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"93 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83160602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-13DOI: 10.19080/ctoij.2019.14.555881
K. Sood
The role of para-aortic lymph nodal irradiation (PALNI) remained undefined so far. Firstly, FIGO staging did not take nodal status into account hence the node positive patients remained an undefined subgroup. Secondly, despite RTOG trials establishing the survival advantage of prophylactic PALNI, it was not advocated due to the fear of adverse toxicity profile. The adoption of more conformal radiation techniques has revisited this issue. As with the recent advances in technology in imaging as well as the treatment techniques, there has been a tremendous improvement in treatment delivery leading to reduction in the incidence of acute as well as late toxicities. The interest in PALNI has also been triggered by the new FIGO staging which has defined and assigned a stage group to the pelvic and paraaortic LN positive cases. With this pretext in mind we review the current status of prophylactic paraaortic irradiation.
{"title":"Prophylactic Para-Aortic Nodal Irradiation in Carcinoma Cervix: To Do or Not to Do?","authors":"K. Sood","doi":"10.19080/ctoij.2019.14.555881","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555881","url":null,"abstract":"The role of para-aortic lymph nodal irradiation (PALNI) remained undefined so far. Firstly, FIGO staging did not take nodal status into account hence the node positive patients remained an undefined subgroup. Secondly, despite RTOG trials establishing the survival advantage of prophylactic PALNI, it was not advocated due to the fear of adverse toxicity profile. The adoption of more conformal radiation techniques has revisited this issue. As with the recent advances in technology in imaging as well as the treatment techniques, there has been a tremendous improvement in treatment delivery leading to reduction in the incidence of acute as well as late toxicities. The interest in PALNI has also been triggered by the new FIGO staging which has defined and assigned a stage group to the pelvic and paraaortic LN positive cases. With this pretext in mind we review the current status of prophylactic paraaortic irradiation.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86582723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-13DOI: 10.19080/ctoij.2019.14.555882
Pawan Kumar
A 12-year-old girl with moderately differentiated squamous cell carcinoma of the lower esophagus is reported because of its rare presentation in this age group. The patient was presented with vomiting and progressive dysphagia with associated weight loss for 3 months. We could not find any known etiological factors association with this patient. The case was treated with External Beam Radiotherapy by 3-Dimensional Conformal Radiotherapy (3DCRT) technique with excellent immediate response.
{"title":"“A Rare Case Report: Carcinoma Esophagus in 12-year-old Girl with Unknown Etiology”","authors":"Pawan Kumar","doi":"10.19080/ctoij.2019.14.555882","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555882","url":null,"abstract":"A 12-year-old girl with moderately differentiated squamous cell carcinoma of the lower esophagus is reported because of its rare presentation in this age group. The patient was presented with vomiting and progressive dysphagia with associated weight loss for 3 months. We could not find any known etiological factors association with this patient. The case was treated with External Beam Radiotherapy by 3-Dimensional Conformal Radiotherapy (3DCRT) technique with excellent immediate response.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84140437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-11DOI: 10.19080/CTOIJ.2019.14.555880
M. Budzik
Introduction: Apocrine carcinoma (AC) is a distinctive and rare type of malignancy, counted to 0.3-4% of all breast cancer cases. It does not have a particular clinical or radiological feature, although it is characterized by the apocrine morphology, estrogen receptor-negative and androgen receptor-positive profile. Material and Methods: Studied material came from biopsies, excisional biopsies and modified radical mastectomies. Examined samples were stained with standard methods including hematoxylin and eosin. To determine the immunohistochemical expression of ER, PR and HER2 receptors appropriate antibodies were used. Results: Among 1,222 patients with breast cancer only 5 of them were diagnosed with apocrine carcinoma (0.4%). All of them were above 50 years old (51-63, mean: 57). Tumor size varied from 1.4 cm to 3.8 cm with a mean size 2.4 cm, while mean size in all 1,222 studied cases counted for 1.9cm. 2 tumors were classified as high-grade (G3), 1 as G2 and 1 as G2. 4 out of 5 tumors did not affect lymph nodes (N0 stage), whereas 1 sample was classified as N2 with 9/19 affected nodes. This observation was consistent with the whole studied group, in which N0 stage made up the largest percentage. Discussion: Presented results suggest that AC is less frequent in premenopausal patients. AC tends to present as noninvasive without nodal involvement and its biological behavior is less aggressive. Due to the fact that AC is definitely rare type of breast cancer, modern medicine has still limited options to offer for its treatment. Further research needs to be conducted in order to develop target therapies for this carcinoma.
{"title":"Apocrine Breast Carcinoma Histopathological Characteristics","authors":"M. Budzik","doi":"10.19080/CTOIJ.2019.14.555880","DOIUrl":"https://doi.org/10.19080/CTOIJ.2019.14.555880","url":null,"abstract":"Introduction: Apocrine carcinoma (AC) is a distinctive and rare type of malignancy, counted to 0.3-4% of all breast cancer cases. It does not have a particular clinical or radiological feature, although it is characterized by the apocrine morphology, estrogen receptor-negative and androgen receptor-positive profile. Material and Methods: Studied material came from biopsies, excisional biopsies and modified radical mastectomies. Examined samples were stained with standard methods including hematoxylin and eosin. To determine the immunohistochemical expression of ER, PR and HER2 receptors appropriate antibodies were used. Results: Among 1,222 patients with breast cancer only 5 of them were diagnosed with apocrine carcinoma (0.4%). All of them were above 50 years old (51-63, mean: 57). Tumor size varied from 1.4 cm to 3.8 cm with a mean size 2.4 cm, while mean size in all 1,222 studied cases counted for 1.9cm. 2 tumors were classified as high-grade (G3), 1 as G2 and 1 as G2. 4 out of 5 tumors did not affect lymph nodes (N0 stage), whereas 1 sample was classified as N2 with 9/19 affected nodes. This observation was consistent with the whole studied group, in which N0 stage made up the largest percentage. Discussion: Presented results suggest that AC is less frequent in premenopausal patients. AC tends to present as noninvasive without nodal involvement and its biological behavior is less aggressive. Due to the fact that AC is definitely rare type of breast cancer, modern medicine has still limited options to offer for its treatment. Further research needs to be conducted in order to develop target therapies for this carcinoma.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83754999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-10DOI: 10.19080/ctoij.2019.14.555879
V. Zaichick
{"title":"Some Trace Element Contents and Ratios in Prostatic Fluid as Ancillary Diagnostic Tools in Distinguishing Between the Benign Prostatic Hyperplasia and Prostate Cancer","authors":"V. Zaichick","doi":"10.19080/ctoij.2019.14.555879","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555879","url":null,"abstract":"","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75396840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-30DOI: 10.19080/ctoij.2019.14.555878
K. Sharun
Hemangiosarcoma is a malignant vascular endothelial tumor affecting canines. It commonly affects older animals and is also characterized by certain breed predilection. Spleen is the most commonly affected organ in canines but skin associated hemangiosarcomas are less frequent. Management of malignant tumors like hemangiosarcoma should be based on multimodal therapy that combines different techniques like surgical excision, chemotherapy, radiation therapy, and immunotherapy. Even though several chemotherapeutic agents are used alone or as in combinations, it was ineffective in producing a desirable increase in the survival period. Newer agents like Paclitaxel and Resveratrol was found to be effective against hemangiosarcoma cell lines in-vitro. But further studies are required for evaluating the in-vivo effects of such chemotherapeutic agents. Further research should be directed to identify effective chemotherapeutic agents like Paclitaxel and Resveratrol that can be used to manage canine hemangiosarcoma clinically without any side effects.
{"title":"Chemotherapeutic Management of Hemangiosarcoma in Canines – An Update","authors":"K. Sharun","doi":"10.19080/ctoij.2019.14.555878","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555878","url":null,"abstract":"Hemangiosarcoma is a malignant vascular endothelial tumor affecting canines. It commonly affects older animals and is also characterized by certain breed predilection. Spleen is the most commonly affected organ in canines but skin associated hemangiosarcomas are less frequent. Management of malignant tumors like hemangiosarcoma should be based on multimodal therapy that combines different techniques like surgical excision, chemotherapy, radiation therapy, and immunotherapy. Even though several chemotherapeutic agents are used alone or as in combinations, it was ineffective in producing a desirable increase in the survival period. Newer agents like Paclitaxel and Resveratrol was found to be effective against hemangiosarcoma cell lines in-vitro. But further studies are required for evaluating the in-vivo effects of such chemotherapeutic agents. Further research should be directed to identify effective chemotherapeutic agents like Paclitaxel and Resveratrol that can be used to manage canine hemangiosarcoma clinically without any side effects.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73448327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：